We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
PUT
Alnylam Pharmaceuticals
ALNY
$38.3B
$35M 7.95%
234,400
+5,800
+3% +$968K
BOXX icon
2
Alpha Architect 1-3 Month Box ETF
BOXX
$13.1B
$33.9M 7.68%
+318,120
New +$33.7M
ROIV icon
3
Roivant Sciences
ROIV
$23.6B
$29.4M 6.68%
2,791,870
+1,535,279
+122% +$16.6M
SPY icon
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$27.2M 6.17%
+52,000
New +$25.9M
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$38.3B
$26.9M 6.11%
180,145
+170,645
+1,796% +$28.5M
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.55B
$22.7M 5.16%
785,655
+584,796
+291% +$15.9M
CYTK icon
7
Cytokinetics
CYTK
$10.6B
$22.4M 5.08%
319,510
+227,428
+247% +$17.6M
KROS icon
8
Keros Therapeutics
KROS
$197M
$22.4M 5.08%
338,243
-350,073
-51% -$20.8M
RPRX icon
9
Royalty Pharma
RPRX
$26.2B
$21.9M 4.97%
721,301
-600,533
-45% -$17.7M
BBIO icon
10
BridgeBio Pharma
BBIO
$16.4B
$17M 3.86%
549,804
+364,667
+197% +$12.4M
MACK
11
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$13.3M 3.02%
902,350
+352,932
+64% +$4.96M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.5B
$7.34M 1.67%
48,584
+2,700
+6% +$385K
ABUS icon
13
Arbutus Biopharma
ABUS
$847M
$5.35M 1.21%
2,074,183
-1,394,641
-40% -$3.61M
TECX
14
Tectonic Therapeutic
TECX
$536M
$5.06M 1.15%
329,571
+325,392
+7,786% +$5.15M
ONC
15
BeOne Medicines Ltd
ONC
$33.9B
$4.93M 1.12%
31,505
+29,477
+1,454% +$4.75M
QQQ icon
16
PUT
Invesco QQQ Trust
QQQ
$436B
$4.44M 1.01%
+10,000
New +$4.29M
ALKS icon
17
Alkermes
ALKS
$8.11B
$4.24M 0.96%
+156,600
New +$4.45M
BBOT
18
BridgeBio Oncology
BBOT
$659M
$4.2M 0.95%
+403,500
New +$4.18M
SRPT icon
19
Sarepta Therapeutics
SRPT
$1.64B
$4.03M 0.91%
31,105
+23,043
+286% +$2.82M
EDR
20
DELISTED
Endeavor Group Holdings, Inc.
EDR
$3.99M 0.91%
155,250
+152,750
+6,110% +$3.74M
ACHV icon
21
Achieve Life Sciences
ACHV
$633M
$3.98M 0.9%
+875,000
New +$3.88M
FUSN
22
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$3.78M 0.86%
+177,200
New +$2.12M
ABSI icon
23
Absci
ABSI
$1.17B
$3.33M 0.76%
+586,984
New +$2.65M
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.28B
$3.3M 0.75%
+180,911
New +$2.88M
FULC icon
25
Fulcrum Therapeutics
FULC
$241M
$3.21M 0.73%
339,825
-297,580
-47% -$2.66M
1
2 3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.